Anakinra vs. Steroids for Gout Attacks in patients with Renal Disease
Research type
Research Study
Full title
A Randomised Controlled Trial of Anakinra vs. Steroids for Gout Attacks in patients with Chronic Renal Disease (ASGARD): a Feasibility study
IRAS ID
160630
Contact name
Gowrie Balasubramaniam
Contact email
Sponsor organisation
Southend University Hospital
Eudract number
2015-001787-19
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 10 months, 0 days
Research summary
Gout is a common condition that affects 1 in 40 people in the UK. It causes very painful "attacks" of joint swelling, redness and tenderness, mostly affecting the foot, ankle, knee, hand and wrist. It is very common in people with kidney disease, who also tend to be older people with other medical conditions such as high blood pressure, heart disease and diabetes. We do not know the safest and best way to treat an attack of gout in these patients. A lot of people are given treatment that can worsen their kidney disease, along with their other medical conditions.
We want to compare the safest treatment currently available, steroids, with a new treatment that is being increasingly used called Anakinra. This treatment stops the action of a chemical called interleukin-1 which has been discovered to play an important role in the acute gout attack. This treatment has already been used in a handful of patients with kidney disease. We feel it may be a better alternative to steroid treatment which can worsen diabetes, and blood pressure if used for a long time. We would like to perform a scientific study comparing these two treatments. This would involve a big expensive study requiring large numbers of patients and large amounts of information to be collected. Before we do a big study like this, we want to perform a small study using smaller numbers of patients. This will then give us information to plan a larger study to answer the question of which treatment may be better, safer and provides the most value for money for the NHS.
REC name
London - Central Research Ethics Committee
REC reference
15/LO/1922
Date of REC Opinion
10 Feb 2016
REC opinion
Further Information Favourable Opinion